Vancouver General Hospital, Vancouver, British Columbia, Canada.
AHEPA University Hospital, Thessaloniki, Greece; Interbalkan European Medical Center, Thessaloniki, Greece.
JACC Cardiovasc Interv. 2017 Feb 27;10(4):391-399. doi: 10.1016/j.jcin.2016.11.029.
Routine device surveillance after successful left atrial appendage closure is recommended to evaluate for intermediate to late complications. The aim of this study was to assess the incidence and clinical impact of these complications on cardiovascular events.
Centers participating in the Amplatzer Cardiac Plug multicenter study were requested to submit their post-procedural transesophageal echocardiograms for independent adjudication. Thirteen of 22 centers contributed all their post-procedural echocardiograms, which included 344 from 605 consecutive patients. These images were submitted to a core laboratory and reviewed by 2 independent experts for peri-device leak, device-associated thrombus, device embolization, device migration, left atrial appendage thrombus, and left atrial thrombus. Clinical events were prospectively collected by each center.
Of the 344 transesophageal echocardiograms, 339 were deemed analyzable. Patients' mean age was 74.4 ± 7.5 years, and 67.3% were men. The mean CHADS score was 2.7 ± 1.3, the mean CHADS-VASc score was 4.3 ± 1.5, and the mean HAS-BLED score was 3.0 ± 1.2. Amplatzer Cardiac Plug implantation was successful in all patients. Periprocedural major adverse events occurred in 2.4%. Median clinical follow-up duration was 355 days (range 179 to 622 days). Follow-up transesophageal echocardiography was performed after a median of 134 days (range 88 to 227 days). Device-associated thrombus was observed in 3.2% and peri-device leak in 12.5% (5.5% minimal, 5.8% mild, 0.6% moderate, 0.6% severe). Neither device-associated thrombus nor peri-device leak was associated with an increased risk for cardiovascular events. Independent predictors of device-associated thrombus were smoking (odds ratio: 5.79; p = 0.017) and female sex (odds ratio: 4.22; p = 0.027).
Following successful left atrial appendage closure with the Amplatzer Cardiac Plug, the presence of peri-device leak was relatively low, and device-associated thrombus was infrequent. Neither was associated with increased risk for thromboembolism.
建议对成功进行左心耳封堵术后的器械进行常规监测,以评估中晚期并发症。本研究旨在评估这些并发症对心血管事件的发生率和临床影响。
参与 Amplatzer 心脏塞多中心研究的中心被要求提交其术后经食管超声心动图进行独立评估。22 个中心中有 13 个中心提交了所有术后的超声心动图,其中包括 605 例连续患者中的 344 例。这些图像被提交给一个核心实验室,由 2 名独立专家对器械周围漏、器械相关血栓、器械栓塞、器械移位、左心耳血栓和左心房血栓进行审查。每个中心都前瞻性地收集临床事件。
在 344 份经食管超声心动图中,339 份被认为可分析。患者的平均年龄为 74.4 ± 7.5 岁,67.3%为男性。平均 CHADS 评分为 2.7 ± 1.3,平均 CHADS-VASc 评分为 4.3 ± 1.5,平均 HAS-BLED 评分为 3.0 ± 1.2。所有患者均成功植入 Amplatzer 心脏塞。围手术期主要不良事件发生率为 2.4%。中位临床随访时间为 355 天(范围 179 至 622 天)。中位随访时间为 134 天(范围 88 至 227 天)进行随访经食管超声心动图检查。3.2%观察到器械相关血栓,12.5%(5.5%轻微,5.8%轻度,0.6%中度,0.6%重度)出现器械周围漏。器械相关血栓或器械周围漏均与心血管事件风险增加无关。器械相关血栓的独立预测因素为吸烟(优势比:5.79;p = 0.017)和女性(优势比:4.22;p = 0.027)。
在成功进行 Amplatzer 心脏塞封堵左心耳后,器械周围漏的发生率相对较低,器械相关血栓也很少见。两者均与血栓栓塞风险增加无关。